tbuckley/cabot-search huggingface dataset:
MRI-US fusion targeted biopsy results in patients without history of prostate biopsy.
Authors: Cayce Nawaf, James Rosoff, Jeffrey Weinreb, Amanda Lu, Angelique Levi, Peter Humphrey, Peter Schulam, Preston Sprenkle
Journal: Journal of Clinical Oncology (2016)

150 Background: Results from 12-core template mapping biopsy (Mbx) and concurrent MRI-US fusion targeted biopsy (Tbx) were compared in 118 men without prior biopsy. Methods: Between 12/2012 and 06/2015, 374 men with an indication for prostate biopsy presented to our institution and underwent pre-biopsy mpMRI followed by 12-core standard trans-rectal mapping biopsy (Mbx) and MRI-Ultrasound fusion targeted biopsy (Tbx) of lesions identified on mpMRI. The combination of Mbx and Tbx, when both occurred, constitutes a fusion biopsy (Fbx). Men who underwent both Mbx with or without Tbx using the Artemis/Pro-Fuse system with no previous biopsy were included. Patients without a lesion on MRI underwent Mbx only. Maximum Gleason scores (GS) was assigned on a per patient basis with Mbx GS available for all patients in the cohort and Tbx GS available only for patients with a lesion visible on MP-MRI. Clinically significant (CS) was defined as GS ≥3+4. GS per patient was compared by chi-square and McNemar’s test. Results: 118 men met inclusion criteria (mean age=64.9, mean PSA=11.5). Prostate cancer was detected in 64 (54%) Fbx cases. Cancer detection rates for Mbx and Tbx were 54% and 57%, respectively. In patients where Fbx identified CS cancer, Tbx was more likely to have identified the cancer than Mbx (96% vs 72%; p &lt; 0.001). Fewer GS 6 cancers were detected by Tbx (n=7) than by Mbx (n=25), and Tbx alone would have prevented the detection of 21 (18%) cases of GS 6 disease. Conversely, more GS≥ 7 (50% of men) was detected on Tbx than on Mbx (33% of men). In total, there were 16 patients (13.5%) that were missed or understaged by Tbx, but only 4 of these patients (3%) were GS≥ 7. In contrast, there were 19 (16%) patients that were missed or understaged by Mbx, but 17 (14%) of these 19 patients harbored GS≥ 7 disease. Conclusions: In biopsy-naive men who are suspected to have prostate cancer, Tbx provides improved detection of CS prostate cancer compared with Mbx while decreasing the detection of low-grade disease. Tbx alone in biopsy-naive men should be considered if missing 3% of CS disease is acceptable. [Table: see text]
Radical Cystectomy and Surgical Quality of Care
Authors: Brent K. Hollenbeck, James E. Montie, John T. Wei
Journal: Journal of the National Comprehensive Cancer Network (2005)

Defining surgical quality is an imperative and substantial undertaking before its measurement and ultimate improvement. This article defines quality of care and a rationale for its measurement. In the context of radical cystectomy for bladder cancer, we describe a conceptual model for measuring quality of care. Finally, we provide a framework for future research by presenting an overview of recent work pertaining to cystectomy and quality of care.
Case 41-1985
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, Betty U. McNeely, David R. Cave, David L. Gang
Journal: New England Journal of Medicine (1985)

Presentation of CaseAn 84-year-old woman was admitted to the hospital because of bloody diarrhea.She was in a stable state of health until three weeks earlier, when diarrhea developed, with the daily passage of 10 to 12 purulent, blood-streaked stools of small volume, particularly after eating. Her undergarments were sometimes stained with feces, especially when she arose from her bed. Constant pain appeared in the left lower abdominal quadrant. On the day of admission a neighbor reported her condition to her physician, and she was admitted to the hospital.The patient was widowed 10 years before admission. She lived . . .
SAT0302 Influence of Vertebral Deformation on the Vertebral Pain Syndrome
Authors: V. Povoroznyuk, T. Orlyk
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Objectives</h3> The aim of our study is to investigate the relation between the intensity of pain in the thoracic and lumbar spine and morphometric parameters of vertebrae in postmenopausal women. <h3>Methods</h3> The presence and intensity of pain syndrome in the thoracic and lumbar spine were assessed using a visual analog scale (VAS). Morphometric analysis of the vertebral parameters was carried out using the VFA software of the dual-energy X-ray densitometer "Prodigy" (GE Medical systems, Lunar, model 8743, 2005). <h3>Results</h3> The intensity of pain syndrome in the lumbar spine significantly correlates with L1 vertebral indices: A/P (r=-0.37, p=0.01) and M/P (r=-0.29, p=0.03) in women with normal BMD. The intensity of pain in the thoracic region correlates with Th10 vertebral indices: A/P (r=-0.45, p=0.0004) and M/P (r=-0.35, p=0.01) in women with osteopenia. We have not determined any significant relationship between the level of back pain and vertebral body size index in women with osteoporosis and without vertebral fractures. In 11% patients with confirmed wedge and compression vertebral fractures chronic pain syndrome is absent, and the presence of other fractures does not increase the frequency of back pain syndrome (14%). The presence of vertebral fractures significantly increases the risk of pain in the thoracic spine (RR=1.32; 95% CI: 1.09-1.60, p=0.004). In patients with vertebral fractures the intensity of pain in the thoracic spine significantly correlates with indices of Th11-Th12vertebrae, and relates to the number and localization of vertebral fractures. The level of pain in the lumbar region does not depend on the location and number of damaged vertebrae. <h3>Conclusions</h3> In postmenopausal women without osteoporosis and vertebral fractures level of pain may be associated with initial vertebral deformation, limiting the spine transition zone. The presence of vertebral fractures increases the risk of pain syndrome in the thoracic region depending on the location and number of damaged vertebrae. <h3>Disclosure of Interest</h3> None declared
Efficacy of radioimmunotherapy with (<sup>90</sup>Y) ibritumomab tiuxetan is superior as consolidation in relapsed or refractory mantle cell lymphoma: Results of two phase II trials of the European MCL Network and the PLRG
Authors: O. Weigert, W. Jurczak, C. Von Schilling, A. Giza, M. Rummel, A. Hubalewska, A. Pezzutto, M. Unterhalt, W. Hiddemann, A. Skotnicki, M. Dreyling
Journal: Journal of Clinical Oncology (2006)

7533 Background: Radioimmunotherapy (RIT) has demonstrated high clinical efficacy in follicular lymphoma but varying results in mantle cell lymphoma (MCL). Methods: We performed a comparative analysis of two phase II studies with similar inclusion criteria to identify potential predictors of response. 32 patients with relapsed or refractory MCL, WHO performance status ≤2, appropriate hematopoesis (ANC &gt; 1,500/mm 3 , platelets &gt; 100,000/mm 3 ) and adequate function of liver and kidneys were treated with RIT upfront (Arm A, n = 16) or as consolidation after initial cytoreduction (Arm B, n = 16). 28 patients (88%) had been previously treated with rituximab. Patients with &gt;25% bone marrow involvement, known CNS lymphoma, HIV infection or other severe concurrent disease were excluded. Ibritumomab tiuxetan (Zevalin) was applied at a dose of 15 MBq 90 Y/kg, whereas patients with reduced platelet counts (&lt;150,000/mm 3) received 11 MBq 90 Y/kg. Results: The median age was 66.9 years (range 58–72) in Arm A and 63.1 years (range 45–79) in Arm B. The median number of prior regimens was 4 (range 2–6) in Arm A and 1 (1–5) in Arm B. RIT treatment was generally well tolerated with the most common toxicities being hematologic. Thrombocytopenia grade 3 and 4 was observed in 69% of patients, one patient died of hemorrhagic stroke. Granulocytopenia grade 4 occurred in 34% of patients, one patient developed a grade 4 infectious complication. Currently 22 patients are evaluable for response rate and duration of remission (DR). In Arm A a partial response (PR) was observed in 2 of 6 evaluable patients (33.3%) with a median DR of 3.9 months only. In Arm B chemoinduction achieved 2 complete responses (CR) and 14 PR. Following RIT seven of 14 PR patients (50%) converted to CR. Currently, 13 of 16 patients (81%) are still in remission. As expected the most important adverse risk factor was bulky disease before RIT with no responses seen in this patient population. Patients with less prior therapeutic lines (&lt; 2) had significantly higher response rates. Conclusions: In future trials, RIT should be applied earlier in the treatment algorithm of MCL after a debulking strategy with combined immuno-chemotherapy. [Table: see text]
Low Systolic Blood Pressure and Vascular Mortality Among More Than 1 Million Korean Adults
Authors: Sang-Wook Yi, Yejin Mok, Heechoul Ohrr, Jee-Jeon Yi, Young Duk Yun, Jihwan Park, Sun Ha Jee
Journal: Circulation (2016)

The association between low systolic blood pressure (SBP) and vascular disease is unclear, especially in nonclinical populations.We studied 1 235 246 individuals who participated in routine medical examinations between 1992 and 1995. The hazard ratios (HRs) were adjusted for potential confounders. During 22.7 million person-years of follow-up, 34 816 individuals died of atherosclerotic vascular diseases. An increase in SBP was directly related to an increase in vascular mortality at SBP above ≈100 mmHg. The group with the lowest SBP (<90 mm Hg) had a higher HR for mortality from atherosclerotic vascular disease (HR, 1.53; 95% confidence interval, 1.15-2.03) in comparison with those with an SBP of 90 to 99 mm Hg. The HR associated with the lowest SBP was 2.54 (95% confidence interval, 1.51-4.29) for ischemic heart disease and 1.21 (95% confidence interval, 0.79-1.85) for stroke. Regarding stroke subtype, mortality from hemorrhagic stroke (HR per 10 mm Hg increase, 0.53; 95% confidence interval, 0.29-0.96), rather than mortality from ischemic stroke (HR per 10 mm Hg increase, 1.00; 95% confidence interval, 0.51-1.97), was inversely associated with SBP when SBP fell to <100 mm Hg. Even when excluding the first 5 years of follow-up, the HRs associated with the lowest SBP did not decrease. The inverse association between SBP and vascular mortality in the range <100 mm Hg tended to be apparent in people aged 60 to 95 years in comparison with individuals aged 30 to 59 years.J-curve associations exist between SBP and vascular mortality, which reach a nadir at ≈100 mm Hg. SBP of <90 mm Hg may portend death from vascular disease, particularly from ischemic heart disease.
Parenteral CoQ10 Formulation (BPM31510) Significantly Improves Survival In Animal Model Of Leukemia Including The Resolution Of Paraplegia Due To Brain Metastasis
Authors: Niven R Narain, Lucia M Mauro, Viatcheslav R Akmaev, Ely Benaim, Rangaprasad Sarangarajan, Joaquin J Jimenez
Journal: Blood (2013)
TCTAP A-105 Coronary Slow Flow Phenomenon (CSFP) – Assessment of the Role of Endothelial Dysfunction
Authors: Sujai Nikhil Ramakrishnan, Arun prasath Palamalai, Ashwin Lysander, Raghava Chowdary, Ashish Kansal
Journal: Journal of the American College of Cardiology (2016)
Measurement of Mammary Tumor Blood Flow in Unanesthetized Rats2
Authors: Randy Jirtle, Kelly H. Clifton, John H. G. Rankin
Journal: JNCI Journal of the National Cancer Institute (1978)

Journal Article Measurement of Mammary Tumor Blood Flow in Unanesthetized Rats Get access Randy Jirtle, Randy Jirtle 3Radiobiology Laboratories, Departments of Human Oncology and Radiology, University of Wisconsin Medical School, Madison, Wis. 53706 Search for other works by this author on: Oxford Academic PubMed Google Scholar Kelly H. Clifton, Kelly H. Clifton 3Radiobiology Laboratories, Departments of Human Oncology and Radiology, University of Wisconsin Medical School, Madison, Wis. 53706 Search for other works by this author on: Oxford Academic PubMed Google Scholar John H. G. Rankin John H. G. Rankin 5 4Departments of Physiology and Gynecology-Obstetrics, University of Wisconsin Medical School; and Wisconsin Perinatal Center, Madison General Hospital, Madison, Wis. 53715 5Address reprint requests to Dr. John Rankin, Madison General Hospital, 202 South Park St., Madison, Wis. 53715. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 60, Issue 4, April 1978, Pages 881–886, https://doi.org/10.1093/jnci/60.4.881 Published: 01 April 1978 Article history Received: 10 August 1977 Accepted: 02 November 1977 Published: 01 April 1978
Effects of denosumab versus zoledronic acid (ZA) on pain in patients (pts) with advanced cancer (excluding breast and prostate) or multiple myeloma (MM): Results from a randomized phase III clinical trial.
Authors: R. von Moos, D. Patrick, L. Fallowfield, C. S. Cleeland, D. H. Henry, Y. Qian, R. D. Dansey, K. Chung
Journal: Journal of Clinical Oncology (2010)

9043 Background: Treatment of advanced cancer or MM in pts with bisphosphonates prevents osteoclast-mediated skeletal related events (SREs) and improves pain. Previously, denosumab, an investigative fully human monoclonal antibody against RANKL, was shown to be noninferior to ZA in preventing SREs in this pt population. Here, we present pain outcomes from this study. Methods: Eligible pts received subcutaneous denosumab 120 mg or intravenous ZA 4 mg every 4 weeks in a double-blind, double-dummy design. At baseline (BL), day 8, and before each monthly visit, pts completed the Brief Pain Inventory to measure pain severity. Data were analyzed for all randomized pts (N = 1,776) through week 45, when ≥ 50% had dropped out due to death, disease progression, or consent withdrawn. Analyses included clinically significant delay in worsening of pain (≥ 2-point increase from BL) in all pts and in pts with no/mild pain at BL, and the percentage of pts with no/mild pain at BL reporting moderate/severe pain on-study. Results: Pts on denosumab experienced a delay in clinically significant pain worsening compared with pts on ZA (median 169 days: denosumab, 143 days: ZA; HR 0.85, 95% CI: 0.73–0.98, p = 0.02). Among pts with BL scores of no/mild pain (n = 678), median time to moderate/severe pain was also delayed with denosumab (144 days) compared with ZA (102 days; HR 0.81, 95% CI: 0.67–0.99, p = 0.04). The proportion of pts with no/mild pain at BL who reported moderate/severe pain on-study was lower for denosumab than for ZA at most time points (Table). Conclusions: Denosumab prolonged time to worsening of pain compared with ZA. In addition, among pts with no/mild pain at BL, fewer denosumab-treated pts reported moderate/severe pain than ZA-treated pts. Percentage of pts with no/mild pain at BL reporting moderate/severe pain (worst pain score >4) by study week Study week 5 9 13 17 21 25 29 33 37 41 45 Denosumab (N = 361) 21.7 28.3 27.9 26.6 28.3 26.5 29.8 30.4 24.0 23.8 25.3 ZA (N = 317) 24.1 29.7 30.0 29.9 29.9 29.9 26.5 27.0 28.6 29.3 29.7 Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Amgen Amgen, Novartis, Ortho Biotech, Roche, Watson Pharmaceuticals Amgen Amgen, Ortho Biotech, Roche, Watson Pharmaceuticals Amgen, Novartis, Ortho Biotech, Watson Pharmaceuticals
Multiple Primary Neoplasms in Blacks Compared to Whites. III. Initial Cancers of the Female Breast and Uterus 2
Authors: Guy R. Newell, William Rawlings, Edward T. Krementz, Jane D. Roberts
Journal: JNCI Journal of the National Cancer Institute (1974)

Journal Article Multiple Primary Neoplasms in Blacks Compared to Whites. III. Initial Cancers of the Female Breast and Uterus Get access Guy R. Newell, Guy R. Newell Search for other works by this author on: Oxford Academic PubMed Google Scholar William Rawlings, William Rawlings Search for other works by this author on: Oxford Academic PubMed Google Scholar Edward T. Krementz, Edward T. Krementz Search for other works by this author on: Oxford Academic PubMed Google Scholar Jane D. Roberts Jane D. Roberts Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 53, Issue 2, August 1974, Pages 369–373, https://doi.org/10.1093/jnci/53.2.369 Published: 01 August 1974 Article history Received: 19 February 1974 Accepted: 02 May 1974 Published: 01 August 1974
Hyposplenic patients need prophylactic penicillin
Authors: A F Muller, P J Toghill
Journal: BMJ (1994)

should be possible to gather enough data from patients not receiving prophylaxis with penicillin to make the study worth while.Our policy is to counsel patients (or their parents) on the risks of infection; to give them a card containing information on what to do in case of suspected sepsis; to attempt to follow them up annually; and to provide a course of antibiotics (amoxycillin) for them to keep at home for use at the earliest sign of infection.
Bacterial meningitis after intrapartum spinal anesthesia - New York and Ohio, 2008-2009.
Authors: S. de Fijter, M. DiOrio, J. Carmean, J. Schaffzin, M. Quinn, K. Musser, E. Nazarian, M. Moore, B. Beall, R. Gertz, A. Kallen, C. Kim, J. Duffy
Journal: MMWR Morbidity and Mortality Weekly Report (2010)
Specific Delivery of MiRNA for High Efficient Inhibition of Prostate Cancer by RNA Nanotechnology
Authors: Daniel W Binzel, Yi Shu, Hui Li, Meiyan Sun, Qunshu Zhang, Dan Shu, Bin Guo, Peixuan Guo
Journal: Molecular Therapy (2016)

Both siRNA and miRNA can serve as powerful gene-silencing reagents but their specific delivery to cancer cells in vivo without collateral damage to healthy cells remains challenging. We report here the application of RNA nanotechnology for specific and efficient delivery of anti-miRNA seed-targeting sequence to block the growth of prostate cancer in mouse models. Utilizing the thermodynamically ultra-stable three-way junction of the pRNA of phi29 DNA packaging motor, RNA nanoparticles were constructed by bottom-up self-assembly containing the anti-prostate-specific membrane antigen (PSMA) RNA aptamer as a targeting ligand and anti-miR17 or anti-miR21 as therapeutic modules. The 16 nm RNase-resistant and thermodynamically stable RNA nanoparticles remained intact after systemic injection in mice and strongly bound to tumors with little or no accumulation in healthy organs 8 hours postinjection, and subsequently repressed tumor growth at low doses with high efficiency. Both siRNA and miRNA can serve as powerful gene-silencing reagents but their specific delivery to cancer cells in vivo without collateral damage to healthy cells remains challenging. We report here the application of RNA nanotechnology for specific and efficient delivery of anti-miRNA seed-targeting sequence to block the growth of prostate cancer in mouse models. Utilizing the thermodynamically ultra-stable three-way junction of the pRNA of phi29 DNA packaging motor, RNA nanoparticles were constructed by bottom-up self-assembly containing the anti-prostate-specific membrane antigen (PSMA) RNA aptamer as a targeting ligand and anti-miR17 or anti-miR21 as therapeutic modules. The 16 nm RNase-resistant and thermodynamically stable RNA nanoparticles remained intact after systemic injection in mice and strongly bound to tumors with little or no accumulation in healthy organs 8 hours postinjection, and subsequently repressed tumor growth at low doses with high efficiency.
Case 2-1986
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, Betty U. McNeely, B.W. Levine, E.J. Mark
Journal: New England Journal of Medicine (1986)

Presentation of CaseA 58-year-old woman was admitted to the hospital because of fever and pulmonary infiltrates.Approximately 10 years before admission a murmur was noted. Seven years before entry a stroke occurred, with a left-visual-field defect; atrial fibrillation was discovered, with evidence of mitral stenosis. Warfarin and digoxin were administered. One year later exertional dyspnea developed and gradually worsened, with the subsequent appearance of orthopnea and paroxysmal nocturnal dyspnea. Ten months before entry she was admitted to another hospital with pulmonary edema. She was transferred to this hospital, where cardiac catheterization confirmed the presence of mitral stenosis, with a . . .
Case 28-1977
Authors: Richard C. Cabot, Robert E. Scully, James J. Galdabini, Betty U. McNeely, Robert W. Carey, John C. Long
Journal: New England Journal of Medicine (1977)

Presentation of CaseA 77-year-old woman was admitted to the hospital because of an infected hand.Nine years earlier she was found to have a noninvasive transitional-cell carcinoma of the bladder. During the next two years small areas of recurrence were repeatedly fulgurated, and intravesical instillation of thiotepa was begun. Eight months before entry anemia was noted, and further evaluation disclosed pancytopenia, without lymphadenopathy or hepatosplenomegaly. The hematocrit was 17 per cent; the white-cell count was 1300, and the platelet count 66,000. A 25-cell differential count showed 9 neutrophils, 2 band forms, 7 lymphocytes, 4 monocytes, 2 eosinophils and 1 . . .
Purple Crusted Nodules in a Patient With End-stage Liver Disease
Authors: Amanda J. Laska, William A. Miller, Arturo R. Dominguez
Journal: JAMA Dermatology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal